Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 2:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Refractory Partial Onset Seizures Clear all
Completed Phase 2 Interventional Results available

Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam

NCT00152503
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
Seletracetam (UCB44212)
Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • St. Petersburg, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Jun 26, 2026, 2:10 AM EDT
Completed Phase 3 Interventional

A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.

NCT00175890
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
Levetiracetam, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
1 Month to 4 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
42
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Jun 26, 2026, 2:10 AM EDT
Completed Phase 2 Interventional Results available

Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures

NCT00152451
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
Seletracetam (ucb 44212)
Drug
Lead sponsor
UCB S.A. - Pharma Sector
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
7
States / cities
Little Rock, Arkansas • San Francisco, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Jun 26, 2026, 2:10 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06309966
View directory record Official record
Conditions
Focal Epilepsy
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
65
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jun 26, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures

NCT00772603
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Placebo, 2400mg SPN-804, 1200mg SPN-804
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
23
States / cities
Huntsville, Alabama • Northport, Alabama • Phoenix, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Jun 26, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Results available

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures

NCT01713946
View directory record Official record
Conditions
Tuberous Sclerosis Complex-associated Refractory Seizures
Interventions
RAD001, Placebo, Antiepileptic drug (1 to 3 only), open label RAD001 (only used for post-extension phase)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Jun 26, 2026, 2:10 AM EDT
Terminated Phase 3 Interventional Results available

Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

NCT00448539
View directory record Official record
Conditions
Refractory Partial Onset Seizures
Interventions
Rufinamide
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 80 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
27
States / cities
Mobile, Alabama • Little Rock, Arkansas • Bradenton, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Jun 26, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

NCT00699972
View directory record Official record
Conditions
Refractory Partial Seizures
Interventions
E2007 (perampanel), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 99 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Jun 26, 2026, 2:10 AM EDT
Completed Phase 2 Interventional

Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy

NCT06377930
View directory record Official record
Conditions
Focal Onset Seizures
Interventions
RAP-219
Drug
Lead sponsor
Rapport Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
New Haven, Connecticut • Boise, Idaho • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jun 26, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Results available

Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy

NCT00235755
View directory record Official record
Conditions
Seizures
Interventions
Retigabine, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Bethesda, Maryland • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Jun 26, 2026, 2:10 AM EDT
Completed Phase 2 Interventional Results available

A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.

NCT00175825
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, Brivaracetam
Other · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Jun 26, 2026, 2:10 AM EDT
Terminated Not applicable Interventional

RNS System RESPONSE Study

NCT04839601
View directory record Official record
Conditions
Epilepsy, Partial Seizure, Neurostimulator; Complications, Drug Resistant Epilepsy, Focal Epilepsy
Interventions
RNS System
Device
Lead sponsor
NeuroPace
Industry
Eligibility
12 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Grand Rapids, Michigan • Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jun 26, 2026, 2:10 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

NCT04015141
View directory record Official record
Conditions
Pediatric Epileptic Syndrome, Partial-onset Seizures
Interventions
Perampanel Oral Suspension, Perampanel Tablet
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
1 Month to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jun 26, 2026, 2:10 AM EDT
Withdrawn Phase 2 Interventional

Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures

NCT01167335
View directory record Official record
Conditions
Partial Onset Seizures
Interventions
BGG492, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
Mobile, Alabama • Baltimore, Maryland • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Jun 26, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures

NCT01191086
View directory record Official record
Conditions
Epilepsy
Interventions
USL255
Drug
Lead sponsor
Upsher-Smith Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
16
States / cities
Phoenix, Arizona • Ventura, California • Gainsville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2015 · Synced Jun 26, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures

NCT01142193
View directory record Official record
Conditions
Epilepsy
Interventions
USL255, Placebo
Drug
Lead sponsor
Upsher-Smith Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
19
States / cities
Phoenix, Arizona • Ventura, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Jun 26, 2026, 2:10 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06132893
View directory record Official record
Conditions
Focal Epilepsy
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
61
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jun 26, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

NCT00735397
View directory record Official record
Conditions
Epilepsy
Interventions
perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years and older
Enrollment
1,218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Jun 26, 2026, 2:10 AM EDT
Enrolling by invitation Phase 2 Interventional

Long-term Safety and Tolerability of BHV-7000

NCT06443463
View directory record Official record
Conditions
Focal Epilepsy
Interventions
BHV-7000
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
115
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jun 26, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Results available

Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy

NCT00232596
View directory record Official record
Conditions
Seizures
Interventions
Retigabine, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
32
States / cities
Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Jun 26, 2026, 2:10 AM EDT
Completed Phase 2 Interventional

A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures

NCT00105040
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
Levetiracetam, Placebo (PB)
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
4 Years to 16 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2015 · Synced Jun 26, 2026, 2:10 AM EDT
Recruiting Phase 2 Interventional

A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

NCT07219407
View directory record Official record
Conditions
Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure, Focal Seizure, Focal Onset Seizure
Interventions
RAP-219
Drug
Lead sponsor
Rapport Therapeutics Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Boise, Idaho • Rochester, Minnesota • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jun 26, 2026, 2:10 AM EDT
Completed Phase 3 Interventional

Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures

NCT00113815
View directory record Official record
Conditions
Partial Seizure Disorder, Epilepsy, Seizures
Interventions
topiramate, placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
1 Month to 24 Months
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
47
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2014 · Synced Jun 26, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Results available

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

NCT00699582
View directory record Official record
Conditions
Refractory Partial Seizures
Interventions
E2007 (perampanel), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years and older
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
32
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Jun 26, 2026, 2:10 AM EDT